

Patient Enrollment Form for VIMIZIM® (elosulfase alfa)

Fax completed form with prescriber's signature to **1.888.863.3361**
 To learn more about BioMarin RareConnections™ call **1.866.906.6100**,
 hours M–F, 8 AM–8 PM (ET)

All required fields are purple and bolded

PATIENT	First Name		Middle Initial	Last Name		Suffix
	Date of Birth (mm/dd/yyyy)		Gender ☐ Male ☐ Female ☐ Other			
	Address					Floor/Suite/ Unit
	City					State ZIP Code
	Primary Phone		Mobile Phone ☐ (same as primary)		Email	
	Preferred Method of Contact ☐ Primary Phone ☐ Mobile Phone ☐ Email				Preferred Language: ☐ English ☐ Spanish ☐ Other language (please specify)	
	Authorized Representative Name (if applicable)					Relationship to Patient
	Phone			Email		
PRESCRIBER	First Name			Last Name		
	Specialty			NPI Number		
	State License Number		Medicaid Number		Tax ID	
	Name of Institution/Practice					
	Address					Floor/Suite/Unit
	City					State ZIP Code
	Phone		Fax		Email	
	Preferred Method of Contact ☐ Phone ☐ Fax ☐ Email					
	Primary Contact Name (if different from prescriber)					
Phone		Fax		Email		
INSURANCE	Provide copies of all medical and prescription cards — front and back					
	☐ Patient has no insurance					
	Primary Medical Insurance Name					Insurance Phone
	Subscriber Name			Relationship to Patient		
	Member ID		Group		Plan Code	
	Prescription (PBM) Insurance Name					Insurance Phone
	Subscriber Name					
	Member ID		RxBIN		RxPCN RxGROUP	

Patient's Full Name				Date of Birth (mm/dd/yyyy)	
---------------------	--	--	--	----------------------------	--

INFUSION SITE	Infusion Site Name				
	Address				Floor/Suite/Unit
	City			State	ZIP Code
	Infusion Site NPI		Infusion Site Tax ID		Infusion Site Contact (if available)
	Phone		Fax		Email

CLINICAL/DIAGNOSIS	If diagnosis is confirmed please fill out the information below:				
	☐ ICD-10 Code (Morquio A, Mucopolysaccharidosis, E76.210)		☐ Other diagnosis (please specify)		Date of diagnosis (mm/dd/yyyy)
	Lab performing diagnosis				
	Method of diagnosis ☐ Biochemical/Enzyme testing ☐ Molecular testing				
	Patient allergies ☐ NKDA ☐ Yes (please list)				
Concurrent medications					

PRESCRIPTION	For Use by In-Network Specialty Pharmacy Only—Not for Home Infusion				
	Product name: VIMIZIM® (elosulfase alfa), concentrate for infusion			NDC Number: 68135-100-01	
	Current weight (kg)	Date weight measured (mm/dd/yyyy)		Dose (mg per week)	
	Dispense: Number of days' supply/Rx: ☐ 30 days ☐ 90 days Refills: One (1) year			Direction for use: Infuse _____ mg every week in _____ mL normal saline over _____ hours	
	Preferred Procurement Method ☐ Buy and Bill ☐ Specialty Pharmacy				

PRESCRIBER DECLARATION	Prescriber Declaration: I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed VIMIZIM® (elosulfase alfa) based on my professional judgment of medical necessity. I authorize BioMarin or its affiliated companies or subcontractors to forward this prescription electronically, by facsimile, or by mail to a dispensing pharmacy chosen by the above-mentioned patient. I also authorize BioMarin to perform any steps necessary to obtain reimbursement for VIMIZIM, including but not limited to insurance verification and case management. I understand that BioMarin may need additional information, and I agree to provide it as needed for purposes of reimbursement.			
	Prescriber's Signature. Please make a selection			
	Prescriber's Signature/Dispense as Written (no stamps or initials)	Date	Prescriber's Signature/Substitution Permitted (no stamps or initials)	Date
	No stamps or initials: If you are a New York prescriber, please use an original New York State prescription form.			

PATIENT CONSENT FORM

To learn more about BioMarin RareConnections™
call 1.866.906.6100, hours M–F, 8 AM–8 PM (ET)



References to “you,” “your,” “I,” “me,” “my,” etc. in this form are to the patient, even if an authorized representative is signing this form on the patient’s behalf.

FOR BIOMARIN TO ASSIST YOU WITH ITS MEDICINES AND RELATED CARE, YOU WILL NEED TO PROVIDE CONSENT TO BOTH YOUR HEALTHCARE PROVIDER AND BIOMARIN:

- Your healthcare provider needs your written consent to release your protected health information (PHI) to BioMarin
- BioMarin needs your written consent to share your information with service providers such as laboratories and pharmacies to assist you with accessing services that support your treatment
- BioMarin needs your consent to contact you with marketing and other communications about BioMarin’s products, services, programs, and other topics of interest for marketing, educational, or other purposes; to assist you in getting help through additional services that support your treatment plan; and to allow you to provide feedback to BioMarin through market research
- As described below, your consent is voluntary and is not required for treatment, medications, or other care. Your consent is required for BioMarin to provide the product support services described here
- BioMarin and its agents and representatives do not work under the direction of your healthcare provider or give medical advice; they are trained to direct patients to their healthcare provider for treatment-related advice

SECTION A: CONSENT TO SHARE HEALTH INFORMATION FOR PATIENT SUPPORT SERVICES

By signing this Patient Consent Form (PCF), I hereby authorize my healthcare providers, health insurance carriers, laboratory providers, and pharmacy providers (collectively, Healthcare Entities) to use and disclose my individual health and identifying information, including but not limited to health insurance information, medical diagnosis and condition (including but not limited to laboratory test results such as diagnostic results as well as test results related to diagnosis or supportive testing), prescription information, and name, date of birth, sex, address, and telephone number to BioMarin and its agents and representatives, including but not limited to third parties authorized by BioMarin, for them to use for the purposes listed below. I further authorize BioMarin to use my individual health and identifying information to administer the patient support program through BioMarin RareConnections™. Authorized purposes:

- to assist me with accessing services that support my treatment;
- to contact my healthcare provider and collect, enter, and maintain my health information in a database;
- to contact my insurers as needed to verify my insurance coverage, review reimbursement requirements, verify other financial assistance for which I might be eligible, assist with the processing of claims, or otherwise assist in obtaining coverage or financial assistance for my treatment, including but not limited to in relation to post-administration monitoring (n/a for Veteran’s Administration (VA) patients);
- to determine eligibility for program offerings, including but not limited to financial assistance services (financial assistance n/a for VA patients);
- to determine eligibility for a BioMarin Co-Pay Assistance program, valid ONLY for qualifying patients residing in the 50 U.S. states or in Puerto Rico, where not prohibited by law, with commercial insurance, who are not a government beneficiary and/or participant in a federal or state-funded health insurance program, and who have a valid prescription for an FDA-approved indication for the qualifying BioMarin therapy; the BioMarin Co-Pay Assistance program pays for eligible out-of-pocket costs, where applicable, associated with a qualifying BioMarin therapy up to a maximum amount per calendar year;
- to contact me to follow up on any BioMarin RareConnections enrollment requirements, discuss and provide information and education on my treatment and any follow-up requirements, discuss the effectiveness of patient support services, and provide patient support services, education, and adherence reminders such as to take my BioMarin medication; and
- if I sign under Section 3, I further authorize BioMarin to use my individual and health and identifying information for the purposes described in Section B.

Once my health information has been disclosed to BioMarin, I understand that certain federal privacy laws may no longer protect the information. However, BioMarin intends to protect my health information by using and disclosing it only for purposes described in this PCF or as permitted by law or regulations. California residents, to learn more about the information BioMarin may collect about you, how we use that information, and your rights under the California Consumer Privacy Act (CCPA), please review our CCPA Privacy Policy, available at biomarin.com/data-privacy-center. I understand that pharmacy providers, or others working on their behalf, may receive remuneration from BioMarin in exchange for patient therapy support services and data provided.

I understand that any product(s) provided under BioMarin’s temporary Bridge Support program are for my/my child’s personal use and will not be sold, traded, bartered, or transferred. Completing this form does not guarantee that I/my child will qualify for BioMarin’s temporary Bridge Support program. In the event I become eligible for BioMarin’s temporary Bridge Support program, I understand and agree as follows:

- BioMarin Bridge is not health insurance and is available for eligible patients only.
- Offer is available only to patients who have been diagnosed with an FDA-approved indication for a BioMarin therapy.
- No claim for reimbursement for product dispensed pursuant to this program may be submitted to my prescription insurance provider or any other third-party payer, including Medicare.
- To be eligible for Bridge, I/my child must be actively pursuing coverage through my insurance or awaiting a prior authorization/appeal decision.
- BioMarin Bridge does not require, nor will be made contingent on, purchase requirements of any kind.
- BioMarin reserves the right to amend, rescind, or discontinue this program at any time without notification.
- BioMarin Bridge can be dispensed only by the exclusive pharmacy and only after benefits investigation has been completed and a delay occurs in the prior authorization or appeals process or a new-to-market block by the payer has been confirmed.

- BioMarin Bridge is available only to patients in the U.S. and Puerto Rico.
- Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico.
- Additional eligibility criteria may apply. Contact BioMarin RareConnections for details.

This PCF expires in ten (10) years, or such shorter amount of time required by applicable state law, after the date I sign it as indicated by the date next to my signature, unless otherwise canceled earlier as set forth below. I understand I have a right to receive a copy of this PCF.

I understand that I may refuse to sign this PCF. I further understand that my treatment (including with a BioMarin product), payment for treatment, insurance enrollment, or eligibility for insurance benefits are not conditioned upon my agreement to sign this PCF, but if I do not sign it, or if I later cancel it, I will not be able to receive BioMarin's patient support services.

I understand that I may cancel this PCF at any time by mailing a letter to BioMarin at BioMarin RareConnections at 680 Century Point, Lake Mary, FL 32746 or emailing support@biomarin-rareconnections.com. Canceling this PCF will end my consent for my Healthcare Entities to further use and disclose my health information to BioMarin after they are notified of my cancellation but will not affect previous disclosures by them pursuant to this PCF. Canceling this PCF will not affect my ability to receive treatment, payment for treatment, or my eligibility for health insurance.

SECTION B: CONSENT FOR MARKETING/OTHER COMMUNICATIONS

By signing this Patient Consent Form (PCF), I hereby authorize my Healthcare Entities to use and disclose my individual health and identifying information to BioMarin for marketing purposes or to otherwise provide me with information about BioMarin products, services, research, clinical trials, and programs or other topics of interest, and to conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that BioMarin and companies working with BioMarin may use my individual health and identifying information to contact me by mail, email, fax, telephone call, or text message for these purposes. I understand and agree that any information that I provide may be used by BioMarin to help develop new products, services, and programs. I further understand that BioMarin will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission.

1 To authorize your consent, please complete all fields below.

Patient's First Name		Middle Initial	Patient's Last Name		Suffix	Date of Birth	Gender	☐ Male	☐ Female	☐ Other
Patient's/Authorized Representative's Name (if applicable)						Relationship to Patient				
Patient's/Authorized Representative's Address				Floor/Suite/Unit	City	State	ZIP Code			
Preferred Method of Contact (please specify) ☐ Primary Phone _____										
☐ Mobile Phone (leave blank if mobile is primary phone) _____ ☐ Email _____										
Preferred Language ☐ English ☐ Spanish ☐ Other Language (please specify) _____										

2 Please read and sign below.

I have read and understand Section A in this PCF, the Consent to Share Health Information for Patient Support Services, and agree to the terms stated therein. A consent signature is required in order to receive BioMarin services.

Patient's/Authorized Representative's Signature	Date
Print Authorized Representative's Name (if applicable)	Relationship to Patient

3 Please read and sign below.

I have read and understand Section B in this PCF, the Consent for Marketing/Other Communications, and agree to the terms stated therein.

Patient's/Authorized Representative's Signature	Date
Print Authorized Representative's Name (if applicable)	Relationship to Patient

Print and fax your completed form (both pages) to 1.888.863.3361.

Note for healthcare providers: once your patient has completed this form, provide a copy to them and place the original in the patient's medical record.